Colrain Capital’s Novartis NVS Stock Holding History

Colrain Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,464	Closed	-$297K	–	79
2017 Q1	$297K	Sell	4,464 -1,116	-20%	-$74.4K	0.09%	83
2016 Q4	$364K	Buy	+5,580	New	+$362K	0.08%	93

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Colrain Capital's NVS Position: Q2 2017 in Review

Colrain Capital sold out of Novartis (NVS) in Q2 2017, closing a stake of 4,464 shares — an estimated $297K sold.

Colrain Capital first reported a position in NVS in Q4 2016 and held it in 2 quarters. The position peaked at $364K in Q4 2016. 920 funds tracked by Wall St. Rank hold NVS as of Q2 2017.

Colrain Capital reported no remaining Novartis position as of Q2 2017 after selling out during the quarter.
Colrain Capital sold 4,464 Novartis shares in Q2 2017, an estimated $297K.
Colrain Capital first reported a position in Novartis in Q4 2016 and held it in 2 quarters.
Colrain Capital's Novartis position peaked at $364K in Q4 2016.
920 funds tracked by Wall St. Rank held Novartis as of Q2 2017.

Based on Colrain Capital's 13F filing for Q2 2017, filed 10 Aug 2017.